Teva Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Teva Pharma (TEVA) PT Lowered to $9 at Cowen
August 7, 2019 11:14 AM EDTCowen analyst Ken Cacciatore lowered the price target on Teva Pharma (NYSE: TEVA) to $9.00 (from $16.00) while maintaining a Market Perform rating.
The analyst commented, "Teva continues to perform as well as can be expected, with good cost reductions while still investing in Austedo & Ajovy.... More
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Reaffirms Guidance
August 7, 2019 7:01 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.25 billion.
Full year 2019 revenues and EPS guidance reaffirmedFor earnings history and earnings-related data on Teva Pharma (TEVA) click here.
... More